Seelos Therapeutics IncNASDAQ:SEELNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE0.3393
- TODAY'S CHANGE (%)0.0093 (2.8182%)
- Bid / Lots0.3562/ 3
- Ask / Lots0.3700/ 50
- Open / Previous Close0.3420 / 0.3300
- Day Range
- 52 Week Range
- Volume261,455
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | SEEL |
|---|---|---|
| 09:32 ET | 7718 | 0.341 |
| 09:34 ET | 6528 | 0.34 |
| 09:39 ET | 200 | 0.3379 |
| 09:41 ET | 23815 | 0.33 |
| 09:43 ET | 13497 | 0.3302 |
| 09:48 ET | 1400 | 0.3399 |
| 09:50 ET | 100 | 0.34 |
| 09:52 ET | 5050 | 0.347475 |
| 09:54 ET | 740 | 0.347782 |
| 09:56 ET | 2100 | 0.3401 |
| 09:57 ET | 6280 | 0.34 |
| 09:59 ET | 100 | 0.3532 |
| 10:01 ET | 5000 | 0.3451 |
| 10:06 ET | 6450 | 0.34 |
| 10:08 ET | 256 | 0.34 |
| 10:10 ET | 21433 | 0.34 |
| 10:12 ET | 5500 | 0.34 |
| 10:14 ET | 5037 | 0.336 |
| 10:21 ET | 1267 | 0.3399 |
| 10:30 ET | 100 | 0.3399 |
| 10:32 ET | 500 | 0.3399 |
| 10:37 ET | 800 | 0.3399 |
| 10:42 ET | 3552 | 0.3351 |
| 10:51 ET | 400 | 0.3302 |
| 10:53 ET | 513 | 0.3302 |
| 10:57 ET | 450 | 0.332249 |
| 11:04 ET | 1750 | 0.3303 |
| 11:08 ET | 1250 | 0.3401 |
| 11:11 ET | 5077 | 0.3302 |
| 11:13 ET | 1095 | 0.3302 |
| 11:15 ET | 120 | 0.3438 |
| 11:18 ET | 291 | 0.344 |
| 11:29 ET | 300 | 0.34 |
| 11:31 ET | 10222 | 0.34 |
| 11:42 ET | 500 | 0.3396 |
| 11:45 ET | 600 | 0.3396 |
| 11:58 ET | 200 | 0.34 |
| 12:14 ET | 145 | 0.3449 |
| 12:18 ET | 1100 | 0.3411 |
| 12:20 ET | 900 | 0.3411 |
| 12:23 ET | 510 | 0.3486 |
| 12:30 ET | 300 | 0.3486 |
| 12:36 ET | 2519 | 0.3486 |
| 12:45 ET | 2000 | 0.347422 |
| 12:48 ET | 576 | 0.3474 |
| 01:06 ET | 100 | 0.34475 |
| 01:15 ET | 767 | 0.3411 |
| 01:17 ET | 175 | 0.347105 |
| 01:21 ET | 350 | 0.3411 |
| 01:26 ET | 11400 | 0.3482 |
| 01:30 ET | 275 | 0.3483 |
| 01:35 ET | 515 | 0.3405 |
| 01:39 ET | 100 | 0.3483 |
| 01:42 ET | 2700 | 0.344 |
| 01:50 ET | 232 | 0.3433 |
| 01:51 ET | 16429 | 0.3481 |
| 01:53 ET | 1300 | 0.3516 |
| 02:06 ET | 6500 | 0.3481 |
| 02:08 ET | 2455 | 0.352 |
| 02:11 ET | 6197 | 0.354899 |
| 02:13 ET | 128 | 0.355 |
| 02:15 ET | 7342 | 0.3481 |
| 02:22 ET | 3100 | 0.3481 |
| 02:24 ET | 1200 | 0.3481 |
| 02:29 ET | 1100 | 0.344199 |
| 02:36 ET | 1485 | 0.3442 |
| 02:51 ET | 525 | 0.348 |
| 02:54 ET | 320 | 0.347918 |
| 02:56 ET | 100 | 0.3443 |
| 03:02 ET | 900 | 0.3443 |
| 03:09 ET | 1932 | 0.3405 |
| 03:12 ET | 922 | 0.3403 |
| 03:16 ET | 1000 | 0.3406 |
| 03:18 ET | 1640 | 0.3402 |
| 03:20 ET | 600 | 0.3403 |
| 03:21 ET | 3000 | 0.3405 |
| 03:30 ET | 905 | 0.341 |
| 03:32 ET | 395 | 0.3415 |
| 03:34 ET | 1900 | 0.3415 |
| 03:36 ET | 3967 | 0.335 |
| 03:50 ET | 5000 | 0.3382 |
| 03:56 ET | 185 | 0.3401 |
| 03:57 ET | 100 | 0.3435 |
| 03:59 ET | 700 | 0.3393 |
Apr 29, 2024
Seelos Therapeutics Announces Strategic Focus on Mental Health Initiatives and Provides an Update on Current Discussions of Potential Partnerships and Collaborations, from 8:00AM ET on Monday Apr 29, 2024 by Dow Jones
8:00AM ET on Monday Apr 29, 2024 by Dow JonesPress Release: Seelos Therapeutics Announces Strategic Focus on Mental Health Initiatives and Provides an Update on Current Discussions of Potential Partnerships and Collaborations, from 8:00AM ET on Monday Apr 29, 2024 by Dow Jones
8:00AM ET on Monday Apr 29, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Seelos Therapeutics Inc | 5.5M | 0.0x | --- |
Helix BioMedix Inc | 5.2M | -1.5x | --- |
Xenetic Biosciences Inc | 6.0M | -1.6x | --- |
OpGen Inc | 6.1M | -0.1x | --- |
Ensysce Biosciences Inc | 1.8M | -0.1x | --- |
Drazcanna Inc | 1.4M | -0.1x | --- |
Company Information
Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the development of products that address significant unmet needs in Central Nervous System (CNS) disorders and other rare disorders. The Company operates under one segment which develops pharmaceutical products. The Company's programs include SLS-002 for the potential treatment of acute suicidal ideation and behavior (ASIB) in patients with major depressive disorder (MDD) and SLS-005 for the potential treatment of amyotrophic lateral sclerosis (ALS) and spinocerebellar ataxia (SCA). SLS-002 is intranasal racemic ketamine with two investigational new drug applications (INDs). SLS-005 is used for the potential treatment of Sanfilippo Syndrome. SLS-005 is IV trehalose, a protein stabilizer that crosses the blood-brain barrier and activates autophagy and the lysosomal pathway. The Company's ongoing preclinical programs include SLS-004, SLS-006, and SLS-007.
Contact Information
- Headquarters
- 300 PARK AVENUE, 2ND FLOORNEW YORK, NY, United States 10022
- Phone
- 646-293-2100
- Fax
- 858-436-8155
Executives
- Chairman of the Board
- Richard Pascoe
- President, Chief Executive Officer, Director
- Raj Mehra
- Chief Financial Officer
- Michael Golembiewski
- Director
- Daniel O'Connor
- Independent Director
- Margaret Dalesandro
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $5.5M |
|---|---|
Revenue (TTM) | $2.2M |
Shares Outstanding | 16.6M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 2.01 |
EPS | $-8.95 |
Book Value | $-3.42 |
P/E Ratio | 0.0x |
Price/Sales (TTM) | 2.5 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -2,253.75% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
